Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Journey Medical (DERM) FCF Margin (2020 - 2025)

Journey Medical's FCF Margin history spans 6 years, with the latest figure at 40.65% for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 5828.0% year-over-year to 40.65%, compared with a TTM value of 20.52% through Dec 2025, down 396.0%, and an annual FY2025 reading of 20.32%, up 2345.0% over the prior year.
  • FCF Margin for Q4 2025 was 40.65% at Journey Medical, down from 14.0% in the prior quarter.
  • The five-year high for FCF Margin was 122.7% in Q3 2023, with the low at 108.28% in Q4 2023.
  • Average FCF Margin over 5 years is 17.47%, with a median of 19.93% recorded in 2021.
  • Year-over-year, FCF Margin soared 16788bps in 2023 and then plummeted -13061bps in 2024.
  • Tracing DERM's FCF Margin over 5 years: stood at 18.3% in 2021, then tumbled by -58bps to 28.86% in 2022, then plummeted by -275bps to 108.28% in 2023, then skyrocketed by 116bps to 17.63% in 2024, then plummeted by -331bps to 40.65% in 2025.
  • Per Business Quant, the three most recent readings for DERM's FCF Margin are 40.65% (Q4 2025), 14.0% (Q3 2025), and 6.28% (Q2 2025).